Drug Profile
Mosedipimod - Enzychem Lifesciences
Alternative Names: EC 18; PLAGLatest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Enzychem Lifesciences Corporation
- Developer Enzychem Lifesciences Corporation; Korea Research Institute of Bioscience and Biotechnology
- Class Anti-infectives; Anti-inflammatories; Antigouts; Antineoplastics; Chemoprotectants; Esters; Glycerols; Hepatoprotectants; Palmitic acids; Radioprotectives; Small molecules
- Mechanism of Action Cytokine stimulants; Immunomodulators; Natural killer cell stimulants; Neutrophil stimulants; Pattern recognition receptor modulators; Toll-like receptor 4 expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Acute radiation syndrome; COVID-19 pneumonia; Neutropenia; SARS-CoV-2 acute respiratory disease; Stomatitis
- Preclinical Bladder cancer; Cancer; Gouty arthritis
- No development reported Non-alcoholic steatohepatitis; Sepsis
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in South Korea
- 14 Apr 2023 Pharmacodynamic data from a preclinical studies in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 26 Jul 2022 Phase-II clinical trials in Acute radiation syndrome (PO), before July 2022 (Enzychem Lifesciences pipeline, July 2022)